INS and obesity due to melanocortin 4 receptor deficiency: However, DS20060511 enhances glucose uptake only in the skeletal muscle, and reduces insulin secretion by suppressing the rise in blood glucose levels after glucose loading, thereby suppressing the development of obesity; thus, the compound appears to also offer promise as a drug for the prevention of obesity.